Drug Patents owned by Bayer Healthcare
1. List of Aliqopa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(11 months from now) | |
| USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(6 years from now) | |
| US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
ALIQOPA family patents
7
European Union
5
United States
3
Slovenia
3
Taiwan
3
Japan
3
Denmark
3
Croatia
3
Argentina
3
Spain
3
Ecuador
3
Portugal
3
Cyprus
2
Peru
2
Poland
2
Canada
2
Korea, Republic of
2
Ukraine
2
Brazil
2
Hong Kong
2
China
2
Morocco
2
Malaysia
2
Uruguay
2
Mexico
2
New Zealand
2
Australia
2
South Africa
2
Austria
2
Israel
1
ME
1
Chile
1
Dominican Republic
1
Costa Rica
1
Germany
1
RS
1
Guatemala
1
AP
1
EA
1
Colombia
1
Russia
1
Norway
1
San Marino
1
Tunisia
1
Cuba
1
Singapore
1
Jordan
2. List of Nubeqa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(9 years from now) | |
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 30, 2024 |
| New Indication (I) | Aug 5, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 2023-07-31
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
NUBEQA family patents
16
United States
14
European Union
5
Poland
5
Slovenia
5
Finland
5
Japan
5
Denmark
5
Hungary
5
Spain
5
Portugal
4
Korea, Republic of
4
Brazil
4
Lithuania
4
China
4
RS
4
Croatia
3
Canada
3
Ukraine
3
Australia
3
Israel
2
Chile
2
Hong Kong
2
Cyprus
2
Mexico
2
EA
2
South Africa
1
Georgia
1
Luxembourg
1
Netherlands
1
Malaysia
1
Argentina
1
New Zealand
1
Colombia
1
Norway
1
San Marino
1
Russia
1
Peru
3. List of Vitrakvi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9127013 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US8513263 | BAYER HEALTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(6 years from now) | |
| US10172861 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(12 years from now) | |
| US10799505 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10005783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US9447104 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US10774085 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US9676783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US10047097 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US8865698 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(6 years from now) | |
| US9782414 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(12 years from now) | |
| US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| US10045991 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(13 years from now) | |
| US10668072 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| US11191766 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(13 years from now) | |
| US11484535 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 26, 2025 |
| New Chemical Entity Exclusivity (NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 2022-11-26
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating...
Dosage: SOLUTION;ORAL
VITRAKVI family patents
37
United States
9
Korea, Republic of
9
Japan
8
European Union
7
Taiwan
6
Chile
6
China
6
Australia
6
Russia
6
Singapore
6
Israel
4
Poland
4
Canada
4
Slovenia
4
Philippines
4
Ukraine
4
Brazil
4
Lithuania
4
Denmark
4
Hungary
4
Spain
4
Mexico
4
Portugal
3
Hong Kong
3
Costa Rica
3
Morocco
3
RS
3
Croatia
3
Argentina
3
Colombia
3
Tunisia
3
Cyprus
2
Norway
1
ME
1
Peru
1
Dominican Republic
1
Georgia
1
Cuba
1
Luxembourg
1
Turkey
1
Netherlands
1
Malaysia
1
Uruguay
1
Nicaragua
1
New Zealand
1
San Marino
1
South Africa
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic